Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen

AIDS

Volumn 14, Issue 15, 2000, Pages 2247-2255

  Izopet, J ^a   Massip, P ^a   Souyris, C ^a   Sandres, K ^a   Puissant, B ^a   Obadia, M ^a   Pasquier, C ^a   Bonnet, E ^a   Marchou, B ^a   Puel, J ^a  

^a CHU PURPAN   (France)

Author keywords

Antiretroviral therapy; HIV drug resistance; Protease inhibitors; Reverse transcriptase inhibitors; Salvage therapy; Treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERTANT; SALVAGE THERAPY; T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS LOAD; VIRUS MUTATION;

ADULT; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MICROBIAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROSPECTIVE STUDIES; RNA, VIRAL; SALVAGE THERAPY; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 0033762620     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200010200-00005     Document Type: Article

References (38)

1. HIV treatment failure: Testing for HIV resistance in clinical practice
2. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study
3. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease
4. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
5. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease
6. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
7. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development
8. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
9. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
10. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation
11. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro
12. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
13. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication
14. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay
15. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates
16. Brief report: Primary infection with zidovudine-resistant human immunodeficiency virus type 1
17. Human immunodeficiency virus fitness in vivo: Calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase
18. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215
19. Baseline resistance and virological response to Mega-HAART salvage therapies
20. Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy
21. Avoiding false positives with PCR
22. The neighbor-joining method: A new method for reconstructing phylogenetic trees
23. Protecting HIV databases
24. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype
25. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
26. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment
27. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group
28. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
29. In vivo HIV-1 replicative capacity in early and advanced infection
30. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
31. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
32. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
33. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy
34. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine
35. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
36. HIV-1 genotypic resistance patterns predict response to saquinavir- ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
37. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
38. Virological response to protease inhibitor therapy in an HIV clinic cohort